Gate Neurosciences Is A Clinical Stage Biotechnology Company Based In Carmelindianafounded In 2019The Company Focuses On Developing Precision Therapies Aimed At Improving Brain Health By Targeting Synaptic Dysfunction In Neuropsychiatric And Cognitive Disordersgate Neurosciences Has Raised $41 1 Million In Funding From Notable Investorsincluding Luson Bioventures And Innoviva The Company Specializes In Synaptic Health Therapiesparticularly Through Its Research On Nmda Receptorswhich Play A Crucial Role In Cognition And Mood Regulationgate S Clinical Pipeline Features Apimostinela Single Dose Nmda Positive Allosteric Modulatorpamin Phase 2 Trials For Depressionand Zelquistinela Once Weekly Oral Nmda Pam Also In Phase 2 For Major Depressive Disordertheir Innovative Boost Platform Combines Advanced Research With Human Induced Pluripotent Stem Cells To Enhance The Understanding Of Synaptic Function And Accelerate The Development Of New Therapies
